Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zopiclone
Drug ID BADD_D02397
Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved
ATC Code N05CF01
DrugBank ID DB01198
KEGG ID D01372
MeSH ID C515050
PubChem ID 5735
TTD Drug ID D0ZB7K
NDC Product Code 66639-265; 64330-058; 63190-0030; 65372-1185
UNII 03A5ORL08Q
Synonyms zopiclone | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | Zop | Zopicalma | zopiclodura | Zopiclon AbZ | Zopiclon AL | Zopiclon AZU | Zopiclon beta | Zopiclon Stada | Zopiclon TAD | zopiclon von ct | Zopiclon-neuraxpharm | Zopiclon-TEVA | Zopitan | Zorclone | Imovane | Ximovan | Zimovane | Limovan | Nu-Zopiclone | Optidorm | ratio-Zopiclone | Zopiclon-ratiopharm | Rhovane | RP 27 267 | Siaten | Somnosan | Zileze | Zimoclone | Zopi-Puren | Zopicalm
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 43200-80-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Mental disability26.01.01.001--Not Available
Mental impairment17.03.03.002; 19.21.02.003--Not Available
Middle insomnia19.02.01.003; 17.15.03.003--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Panic attack19.06.04.001--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Personality disorder19.05.02.002--Not Available
Pregnancy18.08.02.004--Not Available
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Rash23.03.13.001--Not Available
Rash papular23.03.13.017--Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retrograde amnesia19.20.01.006; 17.03.02.006--Not Available
Rheumatoid arthritis10.04.06.001; 15.01.03.001--Not Available
Salivary hypersecretion07.06.01.009--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene